Navigation Links
Helix BioPharma to Present at the BioFinance 2009 Conference
Date:4/24/2009

AURORA, Ontario, April 24 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that John Docherty, president and chief operating officer, will present at the BioFinance 2009 Investor Conference at 3:00 p.m. EDT on Wednesday, April 29, at The Toronto Marriott in Toronto. Mr. Docherty will provide an overview of the company's leading technology platforms, DOS47 and Biphasix(TM), and its current product development programs, L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on April 29, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

    For further information contact:

    Investor & Media Relations
    Ian Stone                           Robert Flamm, Ph.D.
    Russo Partners LLC                  Russo Partners LLC
    Tel: (619) 814-3510                 Tel: (212) 845-4226
    Fax: (619) 955-5318                 Email:
    Email:                               robert.flamm@russopartnersllc.com
     ian.stone@russopartnersllc.com     www.russopartnersllc.com

This News Release contains certain forward-looking statements regarding the Company's planned presentation at the BioFinance 2009 Investor Conference and the Company's research and development initiatives, which statements can be identified
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... According to a new market research ... Forecasts (2015-2020), , published by Mordor Intelligence, the Global market ... end of 2020, with North America ... of the global market size. The Global market for Stem ... during the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) ...
(Date:7/29/2015)... - BioAmber Inc. (NYSE: BIOA ) today announced that ... has resigned.  The Company has hired Andrew Ashworth ... December 2014, as full time interim CFO and has ... Andy Ashworth began his employment today, to ... Andy was the Company,s CFO from September 2011 to ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... Alliance, the leading,management consulting firm specializing in the ... Development Practice will,conduct two workshops at the 44th ... June 22 to 26, 2008, at the Boston ... will lead a workshop that examines best,practices for ...
... Ezzet Will Present on the Strategic Value of ... Attributes in Clinical Development, MOUNTAIN VIEW, Calif., ... a leading provider of software, strategic,consulting, and regulatory ... Farkad Ezzet, Ph.D., senior scientist,Pharsight Strategic Consulting Services, ...
... a drug discovery and development company, is pleased,to announce ... Stage,Company of the Year Award by BIOTECanada in the ... have received this prestigious award, one of,BIOTECanada,s four Gold ... and CEO. "This honor is important and made even,more ...
Cached Biology Technology:Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting 2Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting 3Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting 4Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference 2
(Date:7/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) ... Outlook of the Biometrics Industry 2015 " ... global biometrics market is likely to witness significant ... to the uptake of multiple technologies available. The ... the growth of biometrics in existing applications as ...
(Date:7/21/2015)... 2015 Passwords have proven futile for ... recent U.S. Office of Personnel Management breach. Biometric ... conundrum, but developers and end-users are concerned about ... dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today the ... third party integration. A video ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... Biology Letters, Steve Brusatte, Professor Michael Benton, and ... did not proliferate immediately after they originated, but that ... driven by two mass extinctions. "The sheer ... was something special about these animals that preordained them ...
... of the gorgeously-decorated fish which throng Australia,s coral reefs and ... may well be written in their genes. Of particular ... able to re-colonise regions of reef devastated by global warming ... move south, says Dr Line Bay of the ARC Centre ...
... A groundbreaking poll finds that almost half of U.S. ... in 10 Americans say they have heard just a ... of synthetic biology, according to a new report released ... D. Hart Research. Both technologies involve manipulating matter ...
Cached Biology News:Mass extinctions and the evolution of dinosaurs 2Fishy future written in the genes 2Fishy future written in the genes 3Nanotech and synbio: Americans don't know what's coming 2
Request Info...
... Panomer 9 oligodeoxynucleotides are ... labeled at the 5' ... Alexa Fluor dyes and ... assessing microarray spot morphology, ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
Biology Products: